IVVD
Invivyd, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.64
+9.48%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.61
From 52W high−77.90%
Volume3.88M
Market cap$187.64M
P/E (TTM)—
P/S (TTM)3.2x
Div yield—
Key dataNov 4, 2026
Open
$0.61
From 52W high
−77.90%
Volume
3.88M
Market cap
$187.64M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
41.3
MomentumView details →
1D Return
+9.48%
YTD Return
−75.38%
SummaryUpdated Jun 1, 2026
Invivyd, Inc. (NASDAQ:IVVD) is a clinical-stage biopharmaceutical company founded in 2020 and based in Waltham, Massachusetts. Originally incorporated as Adagio Therapeutics, the company went public in August 2021 and later rebranded to Invivyd. The company specializes in developing monoclonal antibody therapies specifically designed to protect immunocompromised patients from infectious diseases, with its primary focus on COVID-19 prevention and treatment. Invivyd has successfully brought its lead product <b>PEMGARDA</b> to market and is actively developing next-generation antibody treatments while expanding its pipeline to include other respiratory viruses.
Similar companies
Latest newsMore news →
Invivyd granted seven newly hired non-executive employees options to purchase an aggregate of 175,000 shares as employment inducements.1d agoInvivyd presented preclinical data on VMS063, an investigational monoclonal antibody candidate for measles, at IDWeek 2026.14d agoInvivyd, Inc. granted six newly hired non-executive employees options to purchase an aggregate of 157,500 shares of its common stock on October 1, 2026, under its 2026 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).30d ago